Utility of morphometry in the study of donor and protocol biopsies D. Serón Servicio de Nefrología Hospital Bellvitge Barcelona.

Slides:



Advertisements
Similar presentations
Biopsias de protocolo:utilidad clínica RSC & NCT Diagnóstico precoz Valor predictivo independiente Variable de eficacia en ensayos clínicos.
Advertisements

Changes in graft function in long term renal transplant recipients – analysis by CKD stage and recipient characteristics U.P.Udayaraj, D.Ansell, R.Steenkamp,
PRA = 36% (21/58) Anti-A11 and B44.
Tuesday Case Conference May Biopsy finding LM –Glomeruli are normal in size to mildly enlarged Mild enlargement of the mesangial areas with occasional.
3. The ASCERTAIN Study. Source Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor.
The Value of Zero-Hour Implantation Biopsies Volker Nickeleit Nephropathology Laboratory, Department of Pathology The University of North Carolina, Chapel.
Renal pathology in other solid organ and bone marrow transplants Anke Schwarz, Deptm. of Nephrology Verena Bröcker, Inst. for Pathology.
AN ANALYSIS OF CADAVER DONOR AND KIDNEY BIOPSY PARAMETERS WITH CORRELATION TO TRANSPLANT OUTCOMES Martin Mozes MD, Mel Schwartz MD, Janis Orlowski MD Michael.
Role of recurrent disease for late allograft loss Fernando G. Cosio Mayo Clinic, Rochester MN 10 th Banff conference on allograft pathology.
C4d staining and morphology in protocol biopsies Michael Mengel* For the ESPRIT-Group European Study Group For Protocol Biopsies In Renal Transplantation.
Impact of expanded criteria donors on patient survival after heart, lung, liver and combined organ transplantation Quebec experience from 2003 to 2009.
Jeremy Chapman Westmead Hospital, Sydney CMV Infection and Allograft Rejection : Are we missing the point?
Sum Scores & Components’ Scores Chronic Scores Acute Rejection Scores Lillian W. Gaber University of Tennessee.
Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University.
The European experience with protocol biopsies Ian Roberts Oxford, UK Oxford Pathology.
Slide Seminar Drugs and Kidney Case 3 Heinz Regele Department of Pathology.
Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.
Evaluation of the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (C-G) formulas in the Calvert equation for Carboplatin Dosing Whitney.
Proteinuria as a Surrogate Outcome in IgA Nephropathy Ron Hogg MD Scott & White Medical Center Temple, Texas.
Estimated GFR Based on Creatinine and Cystatin C
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Agnieszka Perkowska-Ptasinska1, M. Ciszek, A.L. Urbanowicz, L. Paczek,
Comparison of HTK and UW in Abdominal Transplantation Dr. Richard S. Mangus, MD MS Indiana University, School of Medicine.
PREDICTING AKI IS MORE CHALLENGING AS AGE PROGRESSES Sandra Kane-Gill, PharmD, MSc Associate Professor, School of Pharmacy.
Monitoring HLA-specific antibodies
INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
Effectiveness of combination Prednisone–Tacrolimus compared with Prednisone –Cyclosporine in treatment Steroid-Resistant Nephrotic Syndrome Dra. Irma Esther.
Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.
Experience with Calcineurin Inhibitor-Free Immunosuppression in Kidney Transplantation with Marginal Donors Oppenheimer F, Saval N, Gutierrez A, Cam pistol.
© 2010 Universitair Ziekenhuis Gent Population pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients translated into clinical.
Chronic Kidney Disease (CKD) Epidemiology A NEW EPIDEMIC: CHRONIC KIDNEY DISEASE IN GENERAL POPULATION REAL PREVALENCE AND RELATED FACTORS Josep M. Galceran,
Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.
Severe vascular lesions and poor functional outcome
Kidney transplant case Niels Marcussen Hans Dieperink Odense University Hospital.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
The Expanded Criteria Donors in Kidney Transplantation: 3 Years Experience FAM Shaheen, B. Al-Attar, MZ Souqiyyeh, J.E Cillo, A. Al Sayyari.
Humoral rejection: What the pathologist needs to know Humoral rejection: What the pathologist needs to know Heinz Regele Heinz Regele Clinical Institute.
RAPAMUNE ® TM 1 Randomization Variable Day* to Day 386 Randomization Variable Day* to Day 386 RAPA, C min, TN0.765 CsA, C min, TN0.201 Gender0.117 Increasing.
Glomerular lesions in HIV-1-infected patients: evolution from 1996 to 2007 on 88 consecutive renal biopsies. Clara Flateau, François-Xavier Lescure, Emmanuelle.
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
Table 1. Clinicopathological findings at biopsy Clinical Number of patients Age (years) Gender (%Male) eGFR (ml/min/1.73m 2 ) UPE (g/day) Serum albumin.
Supplemental Table A. Baseline proteinuria predicting renal outcome in multivariable Cox-Hazard model PredictorsHR95% CIp value Baseline UPE, g/day
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
C4d in pancreas transplant biopsies: the Leiden experience Ingeborg Bajema Ingeborg Bajema Ingeborg Bajema.
Histological markers of CNI nephrotoxicity: Specific or not specific? Marion Rabant MD, Renaud Snanoudj MD, Virginie Royal MD, C. Girardin, E.Morelon MD.
Background Conclusions low weight, CYP3A5*1 allele, low gamma glutamyl transpeptidase and low hematocrit are associated with a higher tacrolimus clearance.
U # Kidney-pancreas transplant several years ago. Recent increase in creatinine with some proteinuria. Pancreas working well.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Quebec experience from 2003 to 2009 M Carrier MD, JF Lize MD and Quebec transplant programs Impact of Expanded Criteria Donors on outcomes of recipients.
Impact of Recipient and Donor Non-immunological factors on the Outcome of Expanded Criteria Deceased Donors Kidney Transplantation Dr Hajar Al Hayyan.
D. Serón Nephrology Department Hospital Vall d’Hebron Barcelona Interpretation of sequential protocol biopsies in terms of prognosis and clinical implications.
Updates in Diabetic Nephropathy Rodica Pop-Busui, M.D., Ph.D Division of Metabolism, Endocrinology and Diabetes Michigan Comprehensive Diabetes Center.
U # Donor kidney biopsy. Donor 25 yrs old female Blood group: A+ Wt 90 Kg, Ht 180 cm S/P MVA 03 Jan 2007: –Subarachnoid and intracerebral.
Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.
Maurizio Salvadori Careggi University Hospital, Florence Italy
BUONA FUNZIONE RENALE DEI TRAPIANTI RENALI DA DONATORI ANZIANI VALUTATI CON CLEARANCE DELLA CREATININA SECONDO GAULT-COCKCROFT, CON DATI ECOGRAFICI E CON.
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Careggi University Hospital–
Enterprise | Interest Nothing to disclose.
Kidney allocation to highly sensitized patients
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
Renal Pharmacy Group Beginners Lectures 2018
Section 2: AKI Definition
Interplay of subclinical fibrosis
Subclinical rejection in renal transplants is associated with low serum mannose-binding lectin levels  Meritxell Ibernon, Francesc Moreso, Daniel Serón 
Nat. Rev. Nephrol. doi: /nrneph
Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor
Volume 85, Issue 5, Pages (May 2014)
Post-transplant membranous glomerulonephritis as a manifestation of chronic antibody-mediated rejection Hyeon Joo Jeong, Beom Jin Lim, Myoung Soo Kima,
Volume 72, Issue 6, Pages (September 2007)
Presentation transcript:

Utility of morphometry in the study of donor and protocol biopsies D. Serón Servicio de Nefrología Hospital Bellvitge Barcelona

Morphometry Disadvantages Advantages

When is morphometry redundant? When may it be useful? When is it necessary?

Topics Redundant Morphometry applied to the study of donor biopsies Potential utility Mophometric evaluation of protocol biopsies in clinical trials Necessary Glomerular adaptation after renal transplantation

Topics Redundant Morphometry applied to the study of donor biopsies Potential utility Mophometric evaluation of protocol biopsies in clinical trials Necessary Glomerular adaptation after renal transplantation

Preexisting donor damage and outcome yearparameter ____________________________________________________________ LeunissenTransplantation 1989sum of scores Serón NDT 1993Vvint/cortex WangNDT 1998ah, GS Gaber L Transplantation 1995% GS Abdi RTransplantation 1998glomerular size Karpinski Transplantation 1999donor vasculopathy Parmjeet RTransplantation 2000ci, GS Escofet XTransplantation 2003GS _________________________________

Is there any advantage in the morphometric evaluation of donor biopsies?

Evaluation of donor biopsies (June 2000-Dec 2001, N = 77 (  10 glom,  1 art) Banff criteria cg ci ct cv ah mm Quantitative parameters % glomerulosclerosis Vvint/c (%) Vvglom/c (%) Vg x 10 6  3 Vvintima/artery Lopes JA et al. Kidney Int 2005; 67: 1595

Results (1)

Results (2)

Results (3)

Results (4) Multivariate analysis: histologic lesions and 3m CrCl All variables _____________________ 1. Vvint/cortexR= GlomerulosclerosisR=0.62 _____________________ Not including morphometric variables ______________________ 1. Glomerulosclerosis R= cvR= ciR=0.64 ______________________

Conclusions Morphometric evaluation of donor biopsies does not improve the prediction of outcome

Topics Redundant Morphometry applied to the study of donor biopsies Potential utility Mophometric evaluation of protocol biopsies in clinical trials Necessary Glomerular adaptation after renal transplantation

CAN and sequential protocol biopsies Donor biopsies15% 4 th month protocol bx42 % 1 st year protocol bx52% % CAN m

Prevention trial and protocol biopsies m Donor Bx Protocol Bx placebo treatment  Fibrosis  CAN  cv  Vvinterstitium/c  Vvintima/artery

Minimum sample size (50% reduction) (  =0.05,  =0.20) VariablePatients per group ____________________________________  CAN300  Transplant vasc (cv)1200  Vvint/cortex63  Vvintima/artery49 ____________________________________ Serón, Transplantation 2000; 69(9): 1849Moreso et al. Am J Transplantation 2001; 1(1): 82

Conclusions Morphometric evaluation of protocol biopsies in trials aimed to prevent CAN may allow to reduce minimum sample size

Topics Redundant Morphometry applied to the study of donor biopsies Potential utility Mophometric evaluation of protocol biopsies in clinical trials Necessary Glomerular adaptation after renal transplantation

Glomerular number (Ng) Disector /fraccionator (n=56) x 10 6 Hughson M et al Kidney Int 2003; 63: 2113

Ng and Vg in humans Ng/Vg/BSA Hoy WE et al, Kidney Int Suppl 2003; 83, S31

Renal adaptation after transplantation adaptation Ng Vg

Ng RadiologyHistology Morfometry New parameters

Ng in vivo V cortex MRI V vglom/cortex Vg Biopsy Fulladosa X et al J Am Soc Nephrol 2003 ; 14: 2662

Vren and Vcortex by means of a MRI

Volumen renal Vren Volumen cortical Vcort

V glom/cortex y Vg Fulladosa X et al J Am Soc Nephrol 2003

Estimación del número de V cortex * V vglom/cortex Ng =__________________ Vg

Characteristics of patients SCr < 200 mmol/l and proteinuria < 1g/24h 4m protocol biopsy (n=39) Mean  SD ______________________________________ N39 Donor age38  18 Donor sex (male / female)26 / 13 Recipient age46  14 Recipient sex (male / female)24 / 15 Recipient BSA a (sqm)1.74  0.19 Cold ischemia time (hours)20  5 Delayed graft function (no / yes)37 / 2 Serum Creatinine (  mol/l)123  30 Proteinuria g/day0.38  0.47 ______________________________________ Fulladosa X et al J Am Soc Nephrol 2003; 14: 2662

Relationship between Ng and GFR Fulladosa X et al J Am Soc Nephrol 2003; 51: 310

Ng is a major determinant of GFR 2GFR = 9 Ng

Glomerular enlargement after transplantation (n=41) Donor biopsy Recipient biopsy  Vg 04 Alperovich G et al, AJT 2004; 4 : 650

Vg after transplantation Vg Donor BiopsyRecipient Biopsyp _______________________________________________ Ah0.15   0.56NS cg0.10   0.36NS ci0.19   ct0.15   cv0.02   Vg4.1   _______________________________________________ Alperovich G et al, AJT 2004; 4 : 650

Vg y FG a los 4m CrClml/min Vg (x10 6  3 ) Alperovich G et al, AJT 2004; 4 : 650 R=0.38, p=0.01

Glomerular enlargement may be a necessary condition to achieve a good renal function

Epidemiological paradox

 Vg  GFR  Graft Survival  Glomerulosclerosis  Graft Survival ¿Graft Survival?

Vg, GFR and graft survival n=144 patients, protocol biopsy at 4m Donor age (years)37  16(12 – 76) Donor gender (male/female)101 / 43 Patient age (years)47  13(15 – 72) Patient gender (male/female)95 / 49 Panel reactive antibodies (%)7  18(0 – 100) DR mismatches0.6  0.6(0 – 2) Cold ischemia time (hours)22  5(7 – 38) Delayed graft function (no/yes)121 / 23 Acute rejection (no/yes)114 / 30 Time of protocol biopsy (days)125  52(25 – 261) Serum creatinine (  mol/l)140  44(72– 298) Proteinuria (g/day)0.34  0.28(0.03 – 1.00)

Vg, FG y Sup inj n=144 patients protocol biopsy at 4m RR ICp ________________________________ Vg >5 x 10 6  CrCl <60 ml/min ________________________________

Vg, CrCl and Graft survival n=144 biopsia de protocolo 6m > 10 glom CrCl (Cockroft & Gault  60 ml/min/1.73m2 < 60 ml/min/1.73m2 High Low  5 x 10 6  3 < 5 x 10 6  3 Large Small Vg (Weibel & Gomez)

Vg, FG, GS 0,2,4,6,8 1 Cum. Survival Time (months) Vg > 5 & GFR > 60 GS 73% Vg 60GS 95% Vg > 5 & GFR < 60GS 45% Vg < 5 & GFR < 60GS 78%

Conclusion Glomerular volume and renal function are independent predictors of graft survival

Summary

Acknoledgements Francesc Moreso Xavier Fulladosa Miguel Hueso José Antonio Lopes Meritxell Ibernon Gabriela Alperovich Montserrat Gomà Marta Carrera Josep Maria Cruzado Salvador Gil-Vernet Josep Maria Grinyó

Vg small CrCl highn=24(17%) Vg small CrCl lown=60(42%) Vg large CrCl highn=20(20%) Vg large CrCl lown=31(21%)